TENLIFAST-M 500SR / 1000SR Tablets

Better Control Means Better Life



  • Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20 mg + Metformin Hydrochloride IP 500 mg (SR)
  • Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20 mg + Metformin Hydrochloride IP 1000 mg (SR)
  • Diabetes is not just high blood sugar, it means;
  • Risk of stroke
  • Visual disturbance
  • Risk of heart disease
  • High blood pressure
  • Nerve damage
  • Foot problem
  • Possess insulinotropic & glucagonostatic effects that control blood glucose for 24 hours.
  • Safe combination for patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy.


  • In patients with T2DM without increasing risk of hypoglycemia
  • Diabetic patients with cardiovascular diseases
  • Elderly diabetic patients
  • Metformin intolerable patients



  • Exhibits long-lasting & more potent inhibition of the DPP-4 enzyme than sitagliptin, vildagliptin, and alogliptin. 
  • Ensures stabilization of glucose fluctuations throughout the day owing to its long half-life.
  • Imparts sustained effects on glycemic control, thereby reducing the complications of hypoglycemia and weight gain.
  • Safe for patients with renal or liver impairment.


  • Improves glucose tolerance in patients with type-2 diabetes, lowering both basal and postprandial plasma glucose.
  • Positively affect lipid profiles, and improve vascular and hemodynamic indices.


  • Teneligliptin when used as part of dual therapy with metformin leads to significant Glycated Haemoglobin (HbA1c) reduction of 1.07% which incidentally is slightly better compared with phase III trials conducted for the same combination in the Korean population (HbA1c reduction of 0.87% compared to baseline at 16 weeks).
  • Teneligliptin as an add-on to metformin plus sulfonylurea therapy showed a significant (P-value <0.0001) reduction in HbA1c, fasting plasma glucose, and postprandial plasma glucose.
  • While 43.96% of patients receiving teneligliptin + metformin and 35.03% of patients receiving teneligliptin + metformin + sulfonylurea achieved the same target.